Klotho Therapeutics
Biotech firm specializing in developing and commercializing Klotho proteins to combat kidney disease.
Founded
2016Biotech firm specializing in developing and commercializing Klotho proteins to combat kidney disease.
Klotho Therapeutics, founded with a mission to revolutionize aging and disease treatment, focuses on developing and commercializing recombinant human Klotho proteins. The company's core vision is to leverage the therapeutic potential of Klotho proteins to prevent and treat kidney disease and other age-related conditions. By utilizing standard cell culture technology, Klotho Therapeutics aims to make these proteins widely accessible, potentially transforming how society experiences aging.
Notable figures in the company include leading scientists and biotech experts dedicated to advancing Klotho protein research. The company holds worldwide patents pending for its modified, recombinant Klotho proteins. Key achievements include significant progress in the development of these proteins, which are associated with improved cognitive performance and other health benefits. Klotho Therapeutics' impact lies in its potential to address critical health issues related to aging, positioning it as a pioneer in the biotechnology sector focused on longevity and age-related diseases.
Companies similar to Klotho Therapeutics include Klogene Therapeutics, Juvenescence, AgeX Therapeutics and Longeveron.
Klotho Therapeutics was founded in 2016.
Klotho Therapeutics' headquarters is located in San Diego, CA, US.
Klotho Therapeutics' most recent funding round was for $10M (USD) in November 2017.
As of Nov 3, 2017, Klotho Therapeutics has raised a total of $10M (USD).
Klotho Therapeutics has 2 employees as of Feb 4, 2024.
AgeX Therapeutics
